Benzinga | May 18, 2021 06:22AM EDT

HC Wainwright & Co. Initiates Coverage On Redhill Biopharma with Buy Rating, Announces Price Target of $23

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Redhill Biopharma (NASDAQ:RDHL) with a Buy rating and announces Price Target of $23.